nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—CYP17A1—Progesterone—uterine cancer	0.622	0.908	CbGbCtD
Metoclopramide—CYP2D6—Progesterone—uterine cancer	0.0483	0.0705	CbGbCtD
Metoclopramide—CYP2D6—Doxorubicin—uterine cancer	0.0147	0.0215	CbGbCtD
Metoclopramide—Porphyrin metabolism disorder—Progesterone—uterine cancer	0.00865	0.0589	CcSEcCtD
Metoclopramide—Porphyrin metabolism disorder—Medroxyprogesterone Acetate—uterine cancer	0.00784	0.0534	CcSEcCtD
Metoclopramide—Hyperpyrexia—Medroxyprogesterone Acetate—uterine cancer	0.00441	0.03	CcSEcCtD
Metoclopramide—Sunitinib—STK11—uterine cancer	0.00388	0.625	CrCbGaD
Metoclopramide—Menstruation irregular—Progesterone—uterine cancer	0.00327	0.0223	CcSEcCtD
Metoclopramide—Menstruation irregular—Medroxyprogesterone Acetate—uterine cancer	0.00297	0.0202	CcSEcCtD
Metoclopramide—Galactorrhoea—Progesterone—uterine cancer	0.0028	0.019	CcSEcCtD
Metoclopramide—Breast enlargement—Progesterone—uterine cancer	0.0028	0.019	CcSEcCtD
Metoclopramide—Suicidal ideation—Progesterone—uterine cancer	0.00259	0.0176	CcSEcCtD
Metoclopramide—Laryngeal oedema—Medroxyprogesterone Acetate—uterine cancer	0.00256	0.0174	CcSEcCtD
Metoclopramide—Galactorrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00253	0.0173	CcSEcCtD
Metoclopramide—Supraventricular tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.00251	0.0171	CcSEcCtD
Metoclopramide—Sunitinib—FGFR2—uterine cancer	0.00233	0.375	CrCbGaD
Metoclopramide—Laryngospasm—Medroxyprogesterone Acetate—uterine cancer	0.0022	0.015	CcSEcCtD
Metoclopramide—Amenorrhoea—Progesterone—uterine cancer	0.00206	0.0141	CcSEcCtD
Metoclopramide—Blood disorder—Medroxyprogesterone Acetate—uterine cancer	0.00197	0.0134	CcSEcCtD
Metoclopramide—Amenorrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00187	0.0127	CcSEcCtD
Metoclopramide—Fluid retention—Progesterone—uterine cancer	0.00172	0.0117	CcSEcCtD
Metoclopramide—Hepatotoxicity—Dactinomycin—uterine cancer	0.00166	0.0113	CcSEcCtD
Metoclopramide—Fluid retention—Medroxyprogesterone Acetate—uterine cancer	0.00156	0.0106	CcSEcCtD
Metoclopramide—Visual disturbance—Progesterone—uterine cancer	0.00139	0.00946	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Medroxyprogesterone Acetate—uterine cancer	0.00131	0.00896	CcSEcCtD
Metoclopramide—Visual disturbance—Medroxyprogesterone Acetate—uterine cancer	0.00126	0.00857	CcSEcCtD
Metoclopramide—Laryngospasm—Etoposide—uterine cancer	0.00124	0.00846	CcSEcCtD
Metoclopramide—Hepatotoxicity—Etoposide—uterine cancer	0.0012	0.00818	CcSEcCtD
Metoclopramide—Asthma—Progesterone—uterine cancer	0.00114	0.00775	CcSEcCtD
Metoclopramide—Pollakiuria—Progesterone—uterine cancer	0.00105	0.00716	CcSEcCtD
Metoclopramide—Asthma—Medroxyprogesterone Acetate—uterine cancer	0.00103	0.00702	CcSEcCtD
Metoclopramide—Drowsiness—Progesterone—uterine cancer	0.00101	0.00691	CcSEcCtD
Metoclopramide—Bronchospasm—Medroxyprogesterone Acetate—uterine cancer	0.00101	0.0069	CcSEcCtD
Metoclopramide—Depression—Progesterone—uterine cancer	0.00101	0.00689	CcSEcCtD
Metoclopramide—Jaundice—Progesterone—uterine cancer	0.000989	0.00673	CcSEcCtD
Metoclopramide—Body temperature increased—Carboplatin—uterine cancer	0.000973	0.00663	CcSEcCtD
Metoclopramide—Pollakiuria—Medroxyprogesterone Acetate—uterine cancer	0.000952	0.00648	CcSEcCtD
Metoclopramide—Drowsiness—Medroxyprogesterone Acetate—uterine cancer	0.000919	0.00626	CcSEcCtD
Metoclopramide—Depression—Medroxyprogesterone Acetate—uterine cancer	0.000916	0.00624	CcSEcCtD
Metoclopramide—Jaundice—Medroxyprogesterone Acetate—uterine cancer	0.000896	0.0061	CcSEcCtD
Metoclopramide—Visual impairment—Progesterone—uterine cancer	0.000877	0.00598	CcSEcCtD
Metoclopramide—Rash maculo-papular—Etoposide—uterine cancer	0.000843	0.00574	CcSEcCtD
Metoclopramide—Bradycardia—Medroxyprogesterone Acetate—uterine cancer	0.00084	0.00572	CcSEcCtD
Metoclopramide—Visual impairment—Medroxyprogesterone Acetate—uterine cancer	0.000795	0.00541	CcSEcCtD
Metoclopramide—Nervousness—Progesterone—uterine cancer	0.00077	0.00524	CcSEcCtD
Metoclopramide—Muscle spasms—Progesterone—uterine cancer	0.000762	0.00519	CcSEcCtD
Metoclopramide—Neutropenia—Dactinomycin—uterine cancer	0.000752	0.00512	CcSEcCtD
Metoclopramide—Tremor—Progesterone—uterine cancer	0.000743	0.00506	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Etoposide—uterine cancer	0.000742	0.00506	CcSEcCtD
Metoclopramide—Angioedema—Progesterone—uterine cancer	0.000724	0.00493	CcSEcCtD
Metoclopramide—Palpitations—Progesterone—uterine cancer	0.0007	0.00477	CcSEcCtD
Metoclopramide—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.000698	0.00475	CcSEcCtD
Metoclopramide—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.00069	0.0047	CcSEcCtD
Metoclopramide—Convulsion—Progesterone—uterine cancer	0.000687	0.00468	CcSEcCtD
Metoclopramide—Hypertension—Progesterone—uterine cancer	0.000684	0.00466	CcSEcCtD
Metoclopramide—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.000673	0.00458	CcSEcCtD
Metoclopramide—Anxiety—Progesterone—uterine cancer	0.000672	0.00458	CcSEcCtD
Metoclopramide—Agranulocytosis—Dactinomycin—uterine cancer	0.000669	0.00456	CcSEcCtD
Metoclopramide—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.00066	0.00449	CcSEcCtD
Metoclopramide—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.000656	0.00447	CcSEcCtD
Metoclopramide—Confusional state—Progesterone—uterine cancer	0.000652	0.00444	CcSEcCtD
Metoclopramide—Oedema—Progesterone—uterine cancer	0.000647	0.00441	CcSEcCtD
Metoclopramide—Cardiac arrest—Etoposide—uterine cancer	0.00064	0.00436	CcSEcCtD
Metoclopramide—Palpitations—Medroxyprogesterone Acetate—uterine cancer	0.000635	0.00432	CcSEcCtD
Metoclopramide—Tachycardia—Progesterone—uterine cancer	0.000631	0.0043	CcSEcCtD
Metoclopramide—Blood disorder—Epirubicin—uterine cancer	0.000622	0.00424	CcSEcCtD
Metoclopramide—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.000622	0.00424	CcSEcCtD
Metoclopramide—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.000609	0.00415	CcSEcCtD
Metoclopramide—Delirium—Epirubicin—uterine cancer	0.000604	0.00412	CcSEcCtD
Metoclopramide—Hypotension—Progesterone—uterine cancer	0.000604	0.00412	CcSEcCtD
Metoclopramide—Flushing—Dactinomycin—uterine cancer	0.000597	0.00407	CcSEcCtD
Metoclopramide—Amenorrhoea—Epirubicin—uterine cancer	0.000592	0.00403	CcSEcCtD
Metoclopramide—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.000591	0.00403	CcSEcCtD
Metoclopramide—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.000586	0.00399	CcSEcCtD
Metoclopramide—Insomnia—Progesterone—uterine cancer	0.000585	0.00398	CcSEcCtD
Metoclopramide—Dyspnoea—Progesterone—uterine cancer	0.000577	0.00393	CcSEcCtD
Metoclopramide—Blood disorder—Doxorubicin—uterine cancer	0.000576	0.00392	CcSEcCtD
Metoclopramide—Somnolence—Progesterone—uterine cancer	0.000575	0.00392	CcSEcCtD
Metoclopramide—Bronchospasm—Etoposide—uterine cancer	0.000572	0.0039	CcSEcCtD
Metoclopramide—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.000572	0.0039	CcSEcCtD
Metoclopramide—Delirium—Doxorubicin—uterine cancer	0.000559	0.00381	CcSEcCtD
Metoclopramide—Fatigue—Progesterone—uterine cancer	0.000558	0.0038	CcSEcCtD
Metoclopramide—Dyskinesia—Epirubicin—uterine cancer	0.000553	0.00377	CcSEcCtD
Metoclopramide—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000548	0.00373	CcSEcCtD
Metoclopramide—Amenorrhoea—Doxorubicin—uterine cancer	0.000547	0.00373	CcSEcCtD
Metoclopramide—Neutropenia—Etoposide—uterine cancer	0.000544	0.00371	CcSEcCtD
Metoclopramide—Atrioventricular block—Epirubicin—uterine cancer	0.000536	0.00365	CcSEcCtD
Metoclopramide—Feeling abnormal—Progesterone—uterine cancer	0.000533	0.00363	CcSEcCtD
Metoclopramide—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00053	0.00361	CcSEcCtD
Metoclopramide—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000523	0.00356	CcSEcCtD
Metoclopramide—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000521	0.00355	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Epirubicin—uterine cancer	0.00052	0.00354	CcSEcCtD
Metoclopramide—Urticaria—Progesterone—uterine cancer	0.000514	0.0035	CcSEcCtD
Metoclopramide—Dyskinesia—Doxorubicin—uterine cancer	0.000512	0.00349	CcSEcCtD
Metoclopramide—Body temperature increased—Progesterone—uterine cancer	0.000511	0.00348	CcSEcCtD
Metoclopramide—Jaundice—Etoposide—uterine cancer	0.000506	0.00344	CcSEcCtD
Metoclopramide—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000505	0.00344	CcSEcCtD
Metoclopramide—Leukopenia—Dactinomycin—uterine cancer	0.000501	0.00342	CcSEcCtD
Metoclopramide—Atrioventricular block—Doxorubicin—uterine cancer	0.000496	0.00338	CcSEcCtD
Metoclopramide—Fluid retention—Epirubicin—uterine cancer	0.000494	0.00336	CcSEcCtD
Metoclopramide—Agranulocytosis—Etoposide—uterine cancer	0.000484	0.0033	CcSEcCtD
Metoclopramide—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000483	0.00329	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Doxorubicin—uterine cancer	0.000481	0.00328	CcSEcCtD
Metoclopramide—Hypersensitivity—Progesterone—uterine cancer	0.000477	0.00325	CcSEcCtD
Metoclopramide—Rash maculo-papular—Epirubicin—uterine cancer	0.000473	0.00322	CcSEcCtD
Metoclopramide—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000466	0.00317	CcSEcCtD
Metoclopramide—Asthenia—Progesterone—uterine cancer	0.000464	0.00316	CcSEcCtD
Metoclopramide—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000463	0.00316	CcSEcCtD
Metoclopramide—Oedema—Dactinomycin—uterine cancer	0.000457	0.00311	CcSEcCtD
Metoclopramide—Fluid retention—Doxorubicin—uterine cancer	0.000457	0.00311	CcSEcCtD
Metoclopramide—Diarrhoea—Progesterone—uterine cancer	0.000443	0.00301	CcSEcCtD
Metoclopramide—Rash maculo-papular—Doxorubicin—uterine cancer	0.000437	0.00298	CcSEcCtD
Metoclopramide—Flushing—Etoposide—uterine cancer	0.000432	0.00294	CcSEcCtD
Metoclopramide—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000432	0.00294	CcSEcCtD
Metoclopramide—Dizziness—Progesterone—uterine cancer	0.000428	0.00291	CcSEcCtD
Metoclopramide—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000421	0.00286	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Epirubicin—uterine cancer	0.000416	0.00283	CcSEcCtD
Metoclopramide—Rash—Progesterone—uterine cancer	0.000408	0.00278	CcSEcCtD
Metoclopramide—Dermatitis—Progesterone—uterine cancer	0.000407	0.00278	CcSEcCtD
Metoclopramide—Headache—Progesterone—uterine cancer	0.000405	0.00276	CcSEcCtD
Metoclopramide—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000401	0.00273	CcSEcCtD
Metoclopramide—Renal impairment—Epirubicin—uterine cancer	0.000397	0.0027	CcSEcCtD
Metoclopramide—Fatigue—Dactinomycin—uterine cancer	0.000394	0.00268	CcSEcCtD
Metoclopramide—Muscle spasms—Etoposide—uterine cancer	0.00039	0.00265	CcSEcCtD
Metoclopramide—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000388	0.00264	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000385	0.00262	CcSEcCtD
Metoclopramide—Nausea—Progesterone—uterine cancer	0.000384	0.00262	CcSEcCtD
Metoclopramide—Feeling abnormal—Dactinomycin—uterine cancer	0.000377	0.00257	CcSEcCtD
Metoclopramide—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00037	0.00252	CcSEcCtD
Metoclopramide—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000369	0.00251	CcSEcCtD
Metoclopramide—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000367	0.0025	CcSEcCtD
Metoclopramide—Renal impairment—Doxorubicin—uterine cancer	0.000367	0.0025	CcSEcCtD
Metoclopramide—Leukopenia—Etoposide—uterine cancer	0.000363	0.00247	CcSEcCtD
Metoclopramide—Body temperature increased—Dactinomycin—uterine cancer	0.000361	0.00246	CcSEcCtD
Metoclopramide—Cardiac arrest—Epirubicin—uterine cancer	0.000359	0.00244	CcSEcCtD
Metoclopramide—Convulsion—Etoposide—uterine cancer	0.000351	0.00239	CcSEcCtD
Metoclopramide—Hypertension—Etoposide—uterine cancer	0.00035	0.00238	CcSEcCtD
Metoclopramide—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000348	0.00237	CcSEcCtD
Metoclopramide—Hypersensitivity—Dactinomycin—uterine cancer	0.000337	0.00229	CcSEcCtD
Metoclopramide—Confusional state—Etoposide—uterine cancer	0.000334	0.00227	CcSEcCtD
Metoclopramide—Cardiac arrest—Doxorubicin—uterine cancer	0.000332	0.00226	CcSEcCtD
Metoclopramide—Asthenia—Dactinomycin—uterine cancer	0.000328	0.00223	CcSEcCtD
Metoclopramide—Asthma—Epirubicin—uterine cancer	0.000326	0.00222	CcSEcCtD
Metoclopramide—Tachycardia—Etoposide—uterine cancer	0.000323	0.0022	CcSEcCtD
Metoclopramide—Diarrhoea—Dactinomycin—uterine cancer	0.000313	0.00213	CcSEcCtD
Metoclopramide—Hypotension—Etoposide—uterine cancer	0.000309	0.00211	CcSEcCtD
Metoclopramide—Neutropenia—Epirubicin—uterine cancer	0.000305	0.00208	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—uterine cancer	0.000302	0.00206	CcSEcCtD
Metoclopramide—Pollakiuria—Epirubicin—uterine cancer	0.000301	0.00205	CcSEcCtD
Metoclopramide—Dyspnoea—Etoposide—uterine cancer	0.000295	0.00201	CcSEcCtD
Metoclopramide—Somnolence—Etoposide—uterine cancer	0.000294	0.002	CcSEcCtD
Metoclopramide—Drowsiness—Epirubicin—uterine cancer	0.000291	0.00198	CcSEcCtD
Metoclopramide—Rash—Dactinomycin—uterine cancer	0.000288	0.00196	CcSEcCtD
Metoclopramide—Fatigue—Etoposide—uterine cancer	0.000285	0.00194	CcSEcCtD
Metoclopramide—Jaundice—Epirubicin—uterine cancer	0.000283	0.00193	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—uterine cancer	0.000282	0.00192	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—uterine cancer	0.000279	0.0019	CcSEcCtD
Metoclopramide—Feeling abnormal—Etoposide—uterine cancer	0.000273	0.00186	CcSEcCtD
Metoclopramide—Nausea—Dactinomycin—uterine cancer	0.000272	0.00185	CcSEcCtD
Metoclopramide—Agranulocytosis—Epirubicin—uterine cancer	0.000271	0.00185	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—uterine cancer	0.000269	0.00183	CcSEcCtD
Metoclopramide—Bradycardia—Epirubicin—uterine cancer	0.000266	0.00181	CcSEcCtD
Metoclopramide—Urticaria—Etoposide—uterine cancer	0.000263	0.00179	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—uterine cancer	0.000262	0.00179	CcSEcCtD
Metoclopramide—Body temperature increased—Etoposide—uterine cancer	0.000262	0.00178	CcSEcCtD
Metoclopramide—Visual impairment—Epirubicin—uterine cancer	0.000252	0.00171	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—uterine cancer	0.000251	0.00171	CcSEcCtD
Metoclopramide—Bradycardia—Doxorubicin—uterine cancer	0.000246	0.00167	CcSEcCtD
Metoclopramide—Hypersensitivity—Etoposide—uterine cancer	0.000244	0.00166	CcSEcCtD
Metoclopramide—Flushing—Epirubicin—uterine cancer	0.000242	0.00165	CcSEcCtD
Metoclopramide—Asthenia—Etoposide—uterine cancer	0.000237	0.00162	CcSEcCtD
Metoclopramide—Visual impairment—Doxorubicin—uterine cancer	0.000233	0.00159	CcSEcCtD
Metoclopramide—Diarrhoea—Etoposide—uterine cancer	0.000226	0.00154	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—uterine cancer	0.000224	0.00153	CcSEcCtD
Metoclopramide—Nervousness—Epirubicin—uterine cancer	0.000221	0.0015	CcSEcCtD
Metoclopramide—Dizziness—Etoposide—uterine cancer	0.000219	0.00149	CcSEcCtD
Metoclopramide—Muscle spasms—Epirubicin—uterine cancer	0.000218	0.00149	CcSEcCtD
Metoclopramide—Agitation—Epirubicin—uterine cancer	0.000209	0.00142	CcSEcCtD
Metoclopramide—Rash—Etoposide—uterine cancer	0.000209	0.00142	CcSEcCtD
Metoclopramide—Dermatitis—Etoposide—uterine cancer	0.000208	0.00142	CcSEcCtD
Metoclopramide—Headache—Etoposide—uterine cancer	0.000207	0.00141	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—uterine cancer	0.000204	0.00139	CcSEcCtD
Metoclopramide—Leukopenia—Epirubicin—uterine cancer	0.000203	0.00139	CcSEcCtD
Metoclopramide—Muscle spasms—Doxorubicin—uterine cancer	0.000202	0.00138	CcSEcCtD
Metoclopramide—Palpitations—Epirubicin—uterine cancer	0.000201	0.00137	CcSEcCtD
Metoclopramide—Convulsion—Epirubicin—uterine cancer	0.000197	0.00134	CcSEcCtD
Metoclopramide—Nausea—Etoposide—uterine cancer	0.000197	0.00134	CcSEcCtD
Metoclopramide—Hypertension—Epirubicin—uterine cancer	0.000196	0.00134	CcSEcCtD
Metoclopramide—Agitation—Doxorubicin—uterine cancer	0.000193	0.00132	CcSEcCtD
Metoclopramide—Anxiety—Epirubicin—uterine cancer	0.000193	0.00131	CcSEcCtD
Metoclopramide—Leukopenia—Doxorubicin—uterine cancer	0.000188	0.00128	CcSEcCtD
Metoclopramide—Confusional state—Epirubicin—uterine cancer	0.000187	0.00127	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—uterine cancer	0.000186	0.00127	CcSEcCtD
Metoclopramide—Oedema—Epirubicin—uterine cancer	0.000185	0.00126	CcSEcCtD
Metoclopramide—Convulsion—Doxorubicin—uterine cancer	0.000182	0.00124	CcSEcCtD
Metoclopramide—Hypertension—Doxorubicin—uterine cancer	0.000182	0.00124	CcSEcCtD
Metoclopramide—Tachycardia—Epirubicin—uterine cancer	0.000181	0.00123	CcSEcCtD
Metoclopramide—Anxiety—Doxorubicin—uterine cancer	0.000178	0.00122	CcSEcCtD
Metoclopramide—Hypotension—Epirubicin—uterine cancer	0.000173	0.00118	CcSEcCtD
Metoclopramide—Confusional state—Doxorubicin—uterine cancer	0.000173	0.00118	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—uterine cancer	0.000172	0.00117	CcSEcCtD
Metoclopramide—Insomnia—Epirubicin—uterine cancer	0.000168	0.00114	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—uterine cancer	0.000167	0.00114	CcSEcCtD
Metoclopramide—Dyspnoea—Epirubicin—uterine cancer	0.000165	0.00113	CcSEcCtD
Metoclopramide—Somnolence—Epirubicin—uterine cancer	0.000165	0.00112	CcSEcCtD
Metoclopramide—Hypotension—Doxorubicin—uterine cancer	0.00016	0.00109	CcSEcCtD
Metoclopramide—Fatigue—Epirubicin—uterine cancer	0.00016	0.00109	CcSEcCtD
Metoclopramide—Insomnia—Doxorubicin—uterine cancer	0.000155	0.00106	CcSEcCtD
Metoclopramide—Dyspnoea—Doxorubicin—uterine cancer	0.000153	0.00104	CcSEcCtD
Metoclopramide—Feeling abnormal—Epirubicin—uterine cancer	0.000153	0.00104	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—uterine cancer	0.000153	0.00104	CcSEcCtD
Metoclopramide—Fatigue—Doxorubicin—uterine cancer	0.000148	0.00101	CcSEcCtD
Metoclopramide—Urticaria—Epirubicin—uterine cancer	0.000147	0.001	CcSEcCtD
Metoclopramide—Body temperature increased—Epirubicin—uterine cancer	0.000147	0.000999	CcSEcCtD
Metoclopramide—Feeling abnormal—Doxorubicin—uterine cancer	0.000141	0.000963	CcSEcCtD
Metoclopramide—Hypersensitivity—Epirubicin—uterine cancer	0.000137	0.000931	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—uterine cancer	0.000136	0.000929	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—uterine cancer	0.000136	0.000924	CcSEcCtD
Metoclopramide—Asthenia—Epirubicin—uterine cancer	0.000133	0.000906	CcSEcCtD
Metoclopramide—Diarrhoea—Epirubicin—uterine cancer	0.000127	0.000864	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—uterine cancer	0.000126	0.000861	CcSEcCtD
Metoclopramide—Asthenia—Doxorubicin—uterine cancer	0.000123	0.000839	CcSEcCtD
Metoclopramide—Dizziness—Epirubicin—uterine cancer	0.000123	0.000835	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism—AKR1C1—uterine cancer	0.00012	0.000741	CbGpPWpGaD
Metoclopramide—Diarrhoea—Doxorubicin—uterine cancer	0.000117	0.0008	CcSEcCtD
Metoclopramide—Rash—Epirubicin—uterine cancer	0.000117	0.000796	CcSEcCtD
Metoclopramide—Dermatitis—Epirubicin—uterine cancer	0.000117	0.000796	CcSEcCtD
Metoclopramide—Headache—Epirubicin—uterine cancer	0.000116	0.000791	CcSEcCtD
Metoclopramide—CYP2D6—Metapathway biotransformation—AKR1C3—uterine cancer	0.000116	0.000717	CbGpPWpGaD
Metoclopramide—Dizziness—Doxorubicin—uterine cancer	0.000113	0.000773	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism—POLD1—uterine cancer	0.000111	0.000683	CbGpPWpGaD
Metoclopramide—Nausea—Epirubicin—uterine cancer	0.00011	0.00075	CcSEcCtD
Metoclopramide—Rash—Doxorubicin—uterine cancer	0.000108	0.000737	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—uterine cancer	0.000108	0.000736	CcSEcCtD
Metoclopramide—Headache—Doxorubicin—uterine cancer	0.000108	0.000732	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism—RRM2—uterine cancer	0.000107	0.00066	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—DCN—uterine cancer	0.000104	0.000641	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKR1C1—uterine cancer	0.000103	0.000639	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—POLD1—uterine cancer	0.000103	0.000639	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKR1C3—uterine cancer	0.000103	0.000638	CbGpPWpGaD
Metoclopramide—Nausea—Doxorubicin—uterine cancer	0.000102	0.000694	CcSEcCtD
Metoclopramide—HTR4—Signaling Pathways—PGR—uterine cancer	0.000101	0.000622	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CYP11A1—uterine cancer	9.78e-05	0.000604	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKR1C1—uterine cancer	9.67e-05	0.000597	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—YWHAE—uterine cancer	9.61e-05	0.000593	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKR1C3—uterine cancer	9.24e-05	0.00057	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—RRM2—uterine cancer	9.22e-05	0.000569	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—FBXW7—uterine cancer	9.21e-05	0.000569	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—CYP19A1—uterine cancer	9.18e-05	0.000566	CbGpPWpGaD
Metoclopramide—CYP2D6—Metapathway biotransformation—CYP19A1—uterine cancer	9.05e-05	0.000559	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—DCN—uterine cancer	8.95e-05	0.000553	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—RRM2—uterine cancer	8.62e-05	0.000532	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CYP11A1—uterine cancer	8.43e-05	0.000521	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—DCN—uterine cancer	8.37e-05	0.000517	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—STK11—uterine cancer	8.05e-05	0.000497	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CCL2—uterine cancer	8.01e-05	0.000495	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKR1C3—uterine cancer	7.96e-05	0.000492	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CYP11A1—uterine cancer	7.89e-05	0.000487	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—PTEN—uterine cancer	7.59e-05	0.000468	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SOCS3—uterine cancer	7.54e-05	0.000465	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	7.49e-05	0.000462	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKR1C3—uterine cancer	7.45e-05	0.00046	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—CXCL8—uterine cancer	7.45e-05	0.00046	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—EP300—uterine cancer	7.23e-05	0.000447	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CDKN2B—uterine cancer	7.22e-05	0.000445	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CYP19A1—uterine cancer	7.2e-05	0.000444	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—STK11—uterine cancer	7.2e-05	0.000444	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKR1B10—uterine cancer	7.18e-05	0.000443	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IGF1R—uterine cancer	7.01e-05	0.000433	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—CXCL8—uterine cancer	6.98e-05	0.000431	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.76e-05	0.000417	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SMAD3—uterine cancer	6.59e-05	0.000407	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.44e-05	0.000398	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—NRAS—uterine cancer	6.44e-05	0.000398	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CXCL8—uterine cancer	6.33e-05	0.000391	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—FGFR2—uterine cancer	6.28e-05	0.000388	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—STK11—uterine cancer	6.2e-05	0.000383	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CYP19A1—uterine cancer	6.2e-05	0.000383	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RNF43—uterine cancer	5.95e-05	0.000367	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	5.92e-05	0.000365	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.82e-05	0.000359	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—PTEN—uterine cancer	5.81e-05	0.000358	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—STK11—uterine cancer	5.8e-05	0.000358	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CYP19A1—uterine cancer	5.8e-05	0.000358	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	5.73e-05	0.000354	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CCL2—uterine cancer	5.7e-05	0.000352	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—CXCL8—uterine cancer	5.7e-05	0.000352	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—PTEN—uterine cancer	5.68e-05	0.000351	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	5.61e-05	0.000346	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.55e-05	0.000343	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—KRAS—uterine cancer	5.54e-05	0.000342	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—EP300—uterine cancer	5.54e-05	0.000342	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKR1B10—uterine cancer	5.5e-05	0.000339	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.45e-05	0.000336	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—INHBA—uterine cancer	5.44e-05	0.000336	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—EP300—uterine cancer	5.42e-05	0.000334	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—MTHFR—uterine cancer	5.41e-05	0.000334	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKR1B10—uterine cancer	5.38e-05	0.000332	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ESR1—uterine cancer	5.38e-05	0.000332	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.19e-05	0.000321	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—TP53—uterine cancer	5.18e-05	0.00032	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—PIK3CA—uterine cancer	5.09e-05	0.000314	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—NRAS—uterine cancer	5.08e-05	0.000314	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NDUFB11—uterine cancer	4.93e-05	0.000304	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SRD5A2—uterine cancer	4.93e-05	0.000304	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKR1C1—uterine cancer	4.9e-05	0.000303	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	4.8e-05	0.000297	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.77e-05	0.000294	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCL2—uterine cancer	4.73e-05	0.000292	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—MTHFR—uterine cancer	4.66e-05	0.000288	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RNF43—uterine cancer	4.55e-05	0.000281	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	4.53e-05	0.00028	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CXCL8—uterine cancer	4.51e-05	0.000278	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RNF43—uterine cancer	4.46e-05	0.000275	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	4.43e-05	0.000274	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—PIK3CA—uterine cancer	4.43e-05	0.000273	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—KRAS—uterine cancer	4.37e-05	0.00027	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CCL2—uterine cancer	4.36e-05	0.000269	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—MTHFR—uterine cancer	4.36e-05	0.000269	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CCL2—uterine cancer	4.27e-05	0.000264	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—PIK3CA—uterine cancer	4.25e-05	0.000262	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—INHBA—uterine cancer	4.17e-05	0.000257	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	4.13e-05	0.000255	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.11e-05	0.000254	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—INHBA—uterine cancer	4.08e-05	0.000252	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—PIK3CA—uterine cancer	4.02e-05	0.000248	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—TP53—uterine cancer	3.96e-05	0.000245	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ERBB2—uterine cancer	3.95e-05	0.000244	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—TP53—uterine cancer	3.88e-05	0.000239	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.84e-05	0.000237	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	3.8e-05	0.000234	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKR1C3—uterine cancer	3.77e-05	0.000233	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKR1C1—uterine cancer	3.75e-05	0.000232	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CXCL8—uterine cancer	3.74e-05	0.000231	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—HRAS—uterine cancer	3.72e-05	0.00023	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PGR—uterine cancer	3.68e-05	0.000227	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKR1C1—uterine cancer	3.67e-05	0.000227	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CDKN1B—uterine cancer	3.65e-05	0.000226	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—AKT1—uterine cancer	3.62e-05	0.000223	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKR1B1—uterine cancer	3.56e-05	0.00022	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—STAR—uterine cancer	3.56e-05	0.00022	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	3.51e-05	0.000217	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—YWHAE—uterine cancer	3.51e-05	0.000217	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CTNNB1—uterine cancer	3.45e-05	0.000213	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CXCL8—uterine cancer	3.45e-05	0.000213	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CXCL8—uterine cancer	3.38e-05	0.000208	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PTEN—uterine cancer	3.37e-05	0.000208	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FBXW7—uterine cancer	3.36e-05	0.000208	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—AKT1—uterine cancer	3.28e-05	0.000203	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—EP300—uterine cancer	3.21e-05	0.000198	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VEGFA—uterine cancer	3.04e-05	0.000188	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTEN—uterine cancer	3.01e-05	0.000186	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NRAS—uterine cancer	3e-05	0.000185	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STK11—uterine cancer	2.94e-05	0.000181	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCL2—uterine cancer	2.93e-05	0.000181	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKR1C3—uterine cancer	2.89e-05	0.000178	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—EP300—uterine cancer	2.87e-05	0.000177	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKR1C3—uterine cancer	2.83e-05	0.000174	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PGR—uterine cancer	2.81e-05	0.000174	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—POLD1—uterine cancer	2.8e-05	0.000173	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PGR—uterine cancer	2.75e-05	0.00017	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SOCS3—uterine cancer	2.75e-05	0.00017	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—YWHAE—uterine cancer	2.68e-05	0.000166	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN2B—uterine cancer	2.64e-05	0.000163	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—YWHAE—uterine cancer	2.63e-05	0.000162	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKR1C1—uterine cancer	2.62e-05	0.000162	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTEN—uterine cancer	2.59e-05	0.00016	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—KRAS—uterine cancer	2.58e-05	0.00016	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FBXW7—uterine cancer	2.57e-05	0.000159	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1R—uterine cancer	2.56e-05	0.000158	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CXCL8—uterine cancer	2.55e-05	0.000157	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FBXW7—uterine cancer	2.52e-05	0.000155	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—EP300—uterine cancer	2.47e-05	0.000153	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTEN—uterine cancer	2.43e-05	0.00015	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SMAD3—uterine cancer	2.41e-05	0.000149	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PIK3CA—uterine cancer	2.37e-05	0.000147	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—RRM2—uterine cancer	2.33e-05	0.000144	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCL8—uterine cancer	2.31e-05	0.000143	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—EP300—uterine cancer	2.31e-05	0.000143	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—uterine cancer	2.3e-05	0.000142	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FGFR2—uterine cancer	2.29e-05	0.000142	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—DCN—uterine cancer	2.26e-05	0.00014	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STK11—uterine cancer	2.25e-05	0.000139	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL2—uterine cancer	2.24e-05	0.000138	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STK11—uterine cancer	2.2e-05	0.000136	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HRAS—uterine cancer	2.2e-05	0.000136	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL2—uterine cancer	2.19e-05	0.000135	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP11A1—uterine cancer	2.13e-05	0.000132	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PIK3CA—uterine cancer	2.12e-05	0.000131	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SOCS3—uterine cancer	2.11e-05	0.00013	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SOCS3—uterine cancer	2.06e-05	0.000127	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN2B—uterine cancer	2.02e-05	0.000124	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKR1C3—uterine cancer	2.01e-05	0.000124	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN2B—uterine cancer	1.97e-05	0.000122	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ESR1—uterine cancer	1.96e-05	0.000121	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1R—uterine cancer	1.96e-05	0.000121	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL8—uterine cancer	1.95e-05	0.00012	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT1—uterine cancer	1.94e-05	0.00012	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1R—uterine cancer	1.92e-05	0.000118	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL8—uterine cancer	1.91e-05	0.000118	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—NRAS—uterine cancer	1.86e-05	0.000115	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SMAD3—uterine cancer	1.84e-05	0.000114	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CA—uterine cancer	1.83e-05	0.000113	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SMAD3—uterine cancer	1.8e-05	0.000111	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL8—uterine cancer	1.77e-05	0.000109	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGFR2—uterine cancer	1.76e-05	0.000108	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKT1—uterine cancer	1.73e-05	0.000107	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL8—uterine cancer	1.73e-05	0.000107	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL2—uterine cancer	1.73e-05	0.000107	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGFR2—uterine cancer	1.72e-05	0.000106	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CA—uterine cancer	1.71e-05	0.000106	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CA—uterine cancer	1.62e-05	9.98e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KRAS—uterine cancer	1.6e-05	9.86e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—STK11—uterine cancer	1.57e-05	9.69e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP19A1—uterine cancer	1.57e-05	9.69e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ESR1—uterine cancer	1.5e-05	9.27e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKT1—uterine cancer	1.49e-05	9.23e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ESR1—uterine cancer	1.47e-05	9.08e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CA—uterine cancer	1.47e-05	9.06e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ERBB2—uterine cancer	1.44e-05	8.9e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—NRAS—uterine cancer	1.42e-05	8.77e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKT1—uterine cancer	1.4e-05	8.63e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—NRAS—uterine cancer	1.39e-05	8.58e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL8—uterine cancer	1.37e-05	8.44e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HRAS—uterine cancer	1.36e-05	8.38e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN1B—uterine cancer	1.33e-05	8.24e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL2—uterine cancer	1.32e-05	8.17e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT1—uterine cancer	1.32e-05	8.15e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL2—uterine cancer	1.29e-05	7.99e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CTNNB1—uterine cancer	1.26e-05	7.78e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CA—uterine cancer	1.24e-05	7.63e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTEN—uterine cancer	1.23e-05	7.59e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KRAS—uterine cancer	1.22e-05	7.55e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CA—uterine cancer	1.21e-05	7.47e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT1—uterine cancer	1.2e-05	7.4e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KRAS—uterine cancer	1.2e-05	7.39e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MTHFR—uterine cancer	1.18e-05	7.28e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EP300—uterine cancer	1.17e-05	7.24e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CA—uterine cancer	1.12e-05	6.93e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—uterine cancer	1.11e-05	6.85e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB2—uterine cancer	1.1e-05	6.81e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CA—uterine cancer	1.1e-05	6.78e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NRAS—uterine cancer	1.1e-05	6.77e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB2—uterine cancer	1.08e-05	6.66e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL8—uterine cancer	1.05e-05	6.46e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HRAS—uterine cancer	1.04e-05	6.41e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL8—uterine cancer	1.02e-05	6.32e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN1B—uterine cancer	1.02e-05	6.3e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HRAS—uterine cancer	1.02e-05	6.28e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT1—uterine cancer	1.01e-05	6.24e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN1B—uterine cancer	9.99e-06	6.17e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT1—uterine cancer	9.89e-06	6.1e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CTNNB1—uterine cancer	9.65e-06	5.96e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CTNNB1—uterine cancer	9.44e-06	5.83e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KRAS—uterine cancer	9.44e-06	5.83e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTEN—uterine cancer	9.4e-06	5.81e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTEN—uterine cancer	9.2e-06	5.68e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT1—uterine cancer	9.17e-06	5.66e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT1—uterine cancer	8.98e-06	5.54e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EP300—uterine cancer	8.97e-06	5.54e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EP300—uterine cancer	8.78e-06	5.42e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CA—uterine cancer	8.67e-06	5.35e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—uterine cancer	8.49e-06	5.24e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NRAS—uterine cancer	8.39e-06	5.18e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—uterine cancer	8.39e-06	5.18e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—uterine cancer	8.31e-06	5.13e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NRAS—uterine cancer	8.21e-06	5.07e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HRAS—uterine cancer	8.02e-06	4.95e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KRAS—uterine cancer	7.22e-06	4.46e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT1—uterine cancer	7.08e-06	4.37e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KRAS—uterine cancer	7.07e-06	4.36e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CA—uterine cancer	6.63e-06	4.1e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTEN—uterine cancer	6.56e-06	4.05e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CA—uterine cancer	6.49e-06	4.01e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—uterine cancer	6.42e-06	3.96e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—uterine cancer	6.28e-06	3.88e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—EP300—uterine cancer	6.26e-06	3.86e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HRAS—uterine cancer	6.14e-06	3.79e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HRAS—uterine cancer	6.01e-06	3.71e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT1—uterine cancer	5.42e-06	3.35e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT1—uterine cancer	5.3e-06	3.27e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CA—uterine cancer	4.63e-06	2.86e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKT1—uterine cancer	3.78e-06	2.33e-05	CbGpPWpGaD
